Multicentre isradipine dose-confirmation study in Thai patients with hypertension

Area of Science:

• Cardiology
• Pharmacology

Background:

• Isradipine is a dihydropyridine calcium antagonist with vasodilator properties.
• It exhibits minimal negative inotropic effects and is a potent antihypertensive agent.

Purpose of the Study:

• To evaluate the efficacy and tolerability of isradipine in Thai patients with mild to moderate essential hypertension.

Main Methods:

• A single-blind, multicenter study involving 90 patients.
• Included a 2-week placebo pretreatment phase.
• Followed by 8 weeks of isradipine treatment, with dosage titration from 1.25mg to 2.5mg twice daily based on diastolic blood pressure response.

Main Results:

• 80% of patients (72/90) achieved a diastolic blood pressure reduction of ≥10 mm Hg.
• 53% of patients (48/90) reached a diastolic blood pressure of ≤90 mm Hg.
• Isradipine was well tolerated in the study population.

Conclusions:

• Isradipine, particularly at 2.5mg twice daily, is an effective and well-tolerated treatment for mild to moderate essential hypertension in Thai patients.